477 related articles for article (PubMed ID: 35139916)
41. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
42. 27-Hydroxycholesterol increases α-synuclein protein levels through proteasomal inhibition in human dopaminergic neurons.
Schommer J; Marwarha G; Schommer T; Flick T; Lund J; Ghribi O
BMC Neurosci; 2018 Apr; 19(1):17. PubMed ID: 29614969
[TBL] [Abstract][Full Text] [Related]
43. Noninvasive limb remote ischemic preconditioning contributes neuroprotective effects via activation of adenosine A1 receptor and redox status after transient focal cerebral ischemia in rats.
Hu S; Dong H; Zhang H; Wang S; Hou L; Chen S; Zhang J; Xiong L
Brain Res; 2012 Jun; 1459():81-90. PubMed ID: 22560096
[TBL] [Abstract][Full Text] [Related]
44. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
[TBL] [Abstract][Full Text] [Related]
45. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
46. PPARs and Their Neuroprotective Effects in Parkinson's Disease: A Novel Therapeutic Approach in α-Synucleinopathy?
Pérez-Segura I; Santiago-Balmaseda A; Rodríguez-Hernández LD; Morales-Martínez A; Martínez-Becerril HA; Martínez-Gómez PA; Delgado-Minjares KM; Salinas-Lara C; Martínez-Dávila IA; Guerra-Crespo M; Pérez-Severiano F; Soto-Rojas LO
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834679
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
48. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
49. The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma.
Zhou Y; Tong L; Chu X; Deng F; Tang J; Tang Y; Dai Y
Cell Physiol Biochem; 2017; 43(2):733-742. PubMed ID: 28950257
[TBL] [Abstract][Full Text] [Related]
50. Functional Impact of the G279S Substitution in the Adenosine A
Nasrollahi-Shirazi S; Szöllösi D; Yang Q; Muratspahic E; El-Kasaby A; Sucic S; Stockner T; Nanoff C; Freissmuth M
Mol Pharmacol; 2020 Sep; 98(3):250-266. PubMed ID: 32817461
[TBL] [Abstract][Full Text] [Related]
51. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
52. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
53. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
Singh P; Bhat R
ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
[TBL] [Abstract][Full Text] [Related]
54. Aggregation and beyond: alpha-synuclein-based biomarkers in synucleinopathies.
Chopra A; Outeiro TF
Brain; 2024 Jan; 147(1):81-90. PubMed ID: 37526295
[TBL] [Abstract][Full Text] [Related]
55. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
[TBL] [Abstract][Full Text] [Related]
56. NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson's disease.
Song MK; Adams L; Lee JH; Kim YS
PLoS One; 2022; 17(7):e0272085. PubMed ID: 35901090
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques.
Marston HM; Finlayson K; Maemoto T; Olverman HJ; Akahane A; Sharkey J; Butcher SP
J Pharmacol Exp Ther; 1998 Jun; 285(3):1023-30. PubMed ID: 9618404
[TBL] [Abstract][Full Text] [Related]
58. Voltage-dependent anion channel involved in the α-synuclein-induced dopaminergic neuron toxicity in rats.
Lu L; Zhang C; Cai Q; Lu Q; Duan C; Zhu Y; Yang H
Acta Biochim Biophys Sin (Shanghai); 2013 Mar; 45(3):170-8. PubMed ID: 23291291
[TBL] [Abstract][Full Text] [Related]
59. TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease.
Kang SS; Zhang Z; Liu X; Manfredsson FP; Benskey MJ; Cao X; Xu J; Sun YE; Ye K
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10773-10778. PubMed ID: 28923922
[TBL] [Abstract][Full Text] [Related]
60. Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.
Hu Q; Ren X; Liu Y; Li Z; Zhang L; Chen X; He C; Chen JF
Exp Neurol; 2016 Sep; 283(Pt A):213-23. PubMed ID: 27342081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
